Education
About Us
Working with TipRanks
Follow Us
SI-Bone Inc (SIBN)
NASDAQ:SIBN
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operational and financial performance with record revenue, meaningful physician adoption gains, first full-year positive adjusted EBITDA, positive free cash flow in Q4, multiple reimbursement wins, product launches and a strategic distribution partnership. Remaining challenges include a still-present full-year net loss, conservative 2026 guidance reflecting product and partnership ramp timing, expected modest gross margin compression due to capacity investments, and limited international scale. On balance, the positives (high growth, improving profitability, cash generation, reimbursement wins and product pipeline momentum) significantly outweigh the risks and execution/timing uncertainties.Company Guidance
Record Annual Revenue and Strong Growth
Worldwide revenue for 2025 was $200.9 million, a 20.2% year-over-year increase, with fourth quarter revenue of $56.3 million up 15%.
Robust U.S. Adoption and Procedure Growth
U.S. revenue grew 20.6% for the year to $191.1 million driven by a 22% increase in procedure volume; Q4 U.S. revenue was $53.5 million, up 13.9%, and U.S. 2-year stack revenue grew 20.7% (90 bps acceleration vs. Q3).
Expanding Physician Base and Commercial Productivity
Record 1,640 physicians performed procedures in Q4 (addition of 250 physicians, +18% YoY). Over 1,640 active physicians in Q4 and >2,400 U.S. physicians performing nearly 22,000 procedures in 2025. Annual revenue per territory was $2.1 million, +18% YoY, and 13th consecutive quarter of double-digit territory productivity growth.
First Full Year Positive Adjusted EBITDA and Margin Improvement
Delivered positive adjusted EBITDA of $8.9 million for full year 2025 (versus a $5.1 million adjusted EBITDA loss in 2024), a roughly $14 million year-over-year improvement. Q4 adjusted EBITDA was $5.1 million, a 176.2% improvement with a 9.1% adjusted EBITDA margin.
Improved Profitability and Narrowing Net Loss
Q4 net loss narrowed to $1.6 million ($0.04 per diluted share) versus $4.5 million prior-year quarter. Full-year net loss narrowed 38.8% to $18.9 million ($0.44 per diluted share).
Positive Free Cash Flow and Strong Liquidity
Exited 2025 with $147.8 million cash and equivalents (up $2.1 million from Q3). Generated positive free cash flow in Q4 of ~ $0.5 million and full-year cash consumption improved to $2.2 million from $16 million in 2024.
Significant Reimbursement and Regulatory Wins
Secured NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite; Medicare OBL reimbursement for INTRA X increased by 17% effective Jan 1, 2026. Granite benefits from TPT with a $0 device offset (100% facility-reported cost reimbursement).
Product Innovation and Pipeline Momentum
Launched INTRA Ti (alpha launch) and expect commercialization of a third breakthrough device in late 2026 (510(k) filing targeted in Q3). iFuse Bedrock Granite outpaced deformity market growth; iFuse TORQ TNT saw a 50% increase in physician adoption in Q4.
Strategic Commercial Partnership
Entered a strategic partnership with Smith & Nephew to expand trauma reach into Level 1 and Level 2 trauma centers, accelerating penetration of TORQ/TNT and freeing direct sales to focus on spine and interventional markets.
Guidance Showing Continued Growth
2026 revenue guidance of $228.5M to $232.5M implying 14% to 16% YoY growth, with expected gross margin approximately 78% and OpEx growth ~12.5%; company expects increased adjusted EBITDA and continued progress toward free cash flow goals.
SIBN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SIBN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $15.62 | $15.29 | -2.11% |
Nov 10, 2025 | $15.68 | $18.22 | +16.20% |
Aug 04, 2025 | $17.90 | $16.00 | -10.61% |
May 05, 2025 | $14.25 | $16.45 | +15.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does SI-Bone Inc (SIBN) report earnings?
SI-Bone Inc (SIBN) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is SI-Bone Inc (SIBN) earnings time?
SI-Bone Inc (SIBN) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SIBN EPS forecast?
SIBN EPS forecast for the fiscal quarter 2026 (Q1) is -0.19.